PL4243825T3 - Omecamtiv mecarbil w leczeniu niewydolności serca u wybranych grup pacjentów - Google Patents

Omecamtiv mecarbil w leczeniu niewydolności serca u wybranych grup pacjentów

Info

Publication number
PL4243825T3
PL4243825T3 PL21820408.9T PL21820408T PL4243825T3 PL 4243825 T3 PL4243825 T3 PL 4243825T3 PL 21820408 T PL21820408 T PL 21820408T PL 4243825 T3 PL4243825 T3 PL 4243825T3
Authority
PL
Poland
Prior art keywords
treatment
heart failure
patient groups
selected patient
omecamtiv mecarbil
Prior art date
Application number
PL21820408.9T
Other languages
English (en)
Inventor
Narimon HONARPOUR
Fady Malik
Original Assignee
Amgen Inc.
Cytokinetics, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amgen Inc., Cytokinetics, Inc. filed Critical Amgen Inc.
Publication of PL4243825T3 publication Critical patent/PL4243825T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N1/00—Electrotherapy; Circuits therefor
    • A61N1/18—Applying electric currents by contact electrodes
    • A61N1/32—Applying electric currents by contact electrodes alternating or intermittent currents
    • A61N1/38—Applying electric currents by contact electrodes alternating or intermittent currents for producing shock effects
    • A61N1/39—Heart defibrillators
    • A61N1/3956—Implantable devices for applying electric shocks to the heart, e.g. for cardioversion
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cardiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Radiology & Medical Imaging (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
PL21820408.9T 2020-11-12 2021-11-11 Omecamtiv mecarbil w leczeniu niewydolności serca u wybranych grup pacjentów PL4243825T3 (pl)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US202063112995P 2020-11-12 2020-11-12
US202163154077P 2021-02-26 2021-02-26
US202163187084P 2021-05-11 2021-05-11
US202163202873P 2021-06-28 2021-06-28
US202163203436P 2021-07-22 2021-07-22
PCT/US2021/058988 WO2022103966A1 (en) 2020-11-12 2021-11-11 Methods of treating heart failure by administering omecamtiv mecarbil

Publications (1)

Publication Number Publication Date
PL4243825T3 true PL4243825T3 (pl) 2026-03-23

Family

ID=78822539

Family Applications (1)

Application Number Title Priority Date Filing Date
PL21820408.9T PL4243825T3 (pl) 2020-11-12 2021-11-11 Omecamtiv mecarbil w leczeniu niewydolności serca u wybranych grup pacjentów

Country Status (20)

Country Link
US (2) US12194039B2 (pl)
EP (2) EP4243825B1 (pl)
JP (1) JP2024500616A (pl)
KR (1) KR20230107282A (pl)
AU (1) AU2021380754A1 (pl)
CA (1) CA3200673A1 (pl)
CL (2) CL2023001351A1 (pl)
DK (1) DK4243825T3 (pl)
FI (1) FI4243825T3 (pl)
HR (1) HRP20251568T1 (pl)
IL (1) IL302850A (pl)
LT (1) LT4243825T (pl)
MX (1) MX2023005455A (pl)
PL (1) PL4243825T3 (pl)
PT (1) PT4243825T (pl)
RS (1) RS67558B1 (pl)
SI (1) SI4243825T1 (pl)
SM (1) SMT202600073T1 (pl)
TW (1) TW202233189A (pl)
WO (1) WO2022103966A1 (pl)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RS53600B1 (sr) 2004-06-17 2015-02-27 Cytokinetics, Inc. Jedinjenja, preparati i metode
AU2014240049C1 (en) 2013-03-14 2019-03-07 Amgen Inc. Heterocyclic compounds and their uses
FI3645002T3 (fi) 2017-06-30 2025-01-29 Amgen Inc Menetelmiä sydämen vajaatoiminnan hoitamiseksi sydämen sarkomeerin aktivaattoreilla
UA127517C2 (uk) 2017-06-30 2023-09-20 Емджен Інк. Синтез омекамтиву мекарбілу
DK3594199T3 (da) 2018-07-09 2020-09-14 Fis Fabbrica Italiana Sintetici Spa Krystallinsk 2-flour-3-nitrotoluen og proces til forberedelse deraf
AU2019321573B2 (en) 2018-08-17 2025-05-29 Amgen Inc. Salts and crystal forms of omecamtiv mecarbil
US12442027B2 (en) 2018-12-18 2025-10-14 Amgen Inc. Method of reducing aromatic nitro compounds
PL4243825T3 (pl) 2020-11-12 2026-03-23 Amgen Inc. Omecamtiv mecarbil w leczeniu niewydolności serca u wybranych grup pacjentów
JP2024509797A (ja) 2021-03-10 2024-03-05 アムジェン インコーポレイテッド オメカムチブメカルビルの合成
WO2023164452A2 (en) * 2022-02-22 2023-08-31 Yale University Methods of treating, ameliorating, or preventing heart failure, and methods of promoting heart muscle growth
WO2024081611A1 (en) * 2022-10-11 2024-04-18 Cytokinetics, Incorporated Methods for treating heart failure by administering cardiac sarcomere activators
US11986474B1 (en) * 2023-06-27 2024-05-21 Cytokinetics, Incorporated Methods for treating heart failure by administering cardiac sarcomere activators
WO2026050494A1 (en) * 2024-08-29 2026-03-05 Cytokinetics, Incorporated Omecamtiv mecarbil for use in treating heart failure by activating cardiac sarcomere

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4450150A (en) 1973-05-17 1984-05-22 Arthur D. Little, Inc. Biodegradable, implantable drug delivery depots, and method for preparing and using the same
US6303144B1 (en) 1998-02-10 2001-10-16 Welfide Corporation Preparations with controlled release
GB2344287A (en) 1998-12-03 2000-06-07 Ferring Bv Controlled release pharmaceutical formulation
EP1551505B1 (en) 2002-10-04 2010-02-24 Microchips, Inc. Medical device for controlled drug delivery and cardiac monitoring and/or stimulation
RS53600B1 (sr) 2004-06-17 2015-02-27 Cytokinetics, Inc. Jedinjenja, preparati i metode
TW200808321A (en) 2005-12-15 2008-02-16 Cytokinetics Inc Certain chemical entities, compositions and methods
WO2007133747A2 (en) 2006-05-15 2007-11-22 Wisconsin Alumni Research Foundation PULMONARY DELIVERY OF 1α,25-DIHYDROXYVITAMIN D3 AND CO-ADMINISTRATION OF PARATHYROID HORMONE OR CALCITONIN
FR2902092B1 (fr) 2006-06-07 2008-09-05 Sapelem Soc Par Actions Simpli Appareil de manutention de charge
MX2009011275A (es) 2007-04-19 2009-11-02 Dong A Pharm Co Ltd Una composicion de microesferas biodegradables adecuadas para la liberacion controlada de peptido de control de la glucosa y formulacion de la misma.
CA2902424A1 (en) 2013-03-14 2014-09-25 Amgen Inc. Heterocyclic compounds and their uses
AU2014240049C1 (en) 2013-03-14 2019-03-07 Amgen Inc. Heterocyclic compounds and their uses
ES3009592T3 (en) 2015-01-29 2025-03-27 Signal Pharm Llc Isotopologues of 2-(tert-butylamino)-4-((1r,3r,4r)-3-hydroxy-4-methylcyclohexylamino)-pyrimidine-5-carboxamide
JP6858716B2 (ja) 2015-06-26 2021-04-14 アムジエン・インコーポレーテツド 心筋ミオシン活性化剤と洞房結節Ｉｆ電流阻害剤の併用療法
EP3576776A4 (en) 2017-02-06 2020-10-14 Acceleron Pharma Inc. COMPOSITIONS AND METHODS OF TREATMENT OF HEART FAILURE
FI3645002T3 (fi) 2017-06-30 2025-01-29 Amgen Inc Menetelmiä sydämen vajaatoiminnan hoitamiseksi sydämen sarkomeerin aktivaattoreilla
UA127517C2 (uk) 2017-06-30 2023-09-20 Емджен Інк. Синтез омекамтиву мекарбілу
DK3594199T3 (da) 2018-07-09 2020-09-14 Fis Fabbrica Italiana Sintetici Spa Krystallinsk 2-flour-3-nitrotoluen og proces til forberedelse deraf
US11608318B2 (en) 2018-07-12 2023-03-21 Assia Chemical Industries Ltd. Solid state forms of Omecamtiv mecarbil and Omecamtiv mecarbil diHCl
PL3599243T3 (pl) 2018-07-26 2023-08-21 Cvie Therapeutics Limited Związki podobne do 17beta-heterocyklilu naparstnicy do leczenia niewydolności serca
AU2019321573B2 (en) 2018-08-17 2025-05-29 Amgen Inc. Salts and crystal forms of omecamtiv mecarbil
US12442027B2 (en) 2018-12-18 2025-10-14 Amgen Inc. Method of reducing aromatic nitro compounds
BR112021017009A2 (pt) 2019-03-05 2021-11-09 Windtree Therapeutics Inc Formulação intravenosa contendo istaroxima para o tratamento da insuficiência cardíaca aguda (ahf)
US20220348543A1 (en) 2019-09-19 2022-11-03 Synthon B.V. Salts of omecamtiv mecarbil and solid forms thereof
US20220340542A1 (en) 2019-09-19 2022-10-27 Synthon B.V. Salts of omecamtiv mecarbil and solid forms thereof
US20220411374A1 (en) 2019-10-09 2022-12-29 Dr. Reddy's Laboratories Limited Alternate processes for the preparation of omecamtiv mecarbil
US20220402874A1 (en) 2019-10-09 2022-12-22 Dr. Reddy's Laboratories Limited Solid forms of omecamtiv mecarbil dihydrochloride and processes thereof
CA3157629A1 (en) 2019-11-10 2021-05-14 MyoKardia, Inc. Methods of treatment with myosin modulator
GB201918853D0 (en) 2019-12-19 2020-02-05 Lund Lars H Methods of treatment
WO2021136477A1 (zh) 2020-01-03 2021-07-08 苏州科睿思制药有限公司 化合物i二盐酸盐的共晶及其制备方法和用途
EP4103159A1 (en) 2020-02-10 2022-12-21 Amgen Inc. Omecamtiv mecarbil tablet
PL4243825T3 (pl) 2020-11-12 2026-03-23 Amgen Inc. Omecamtiv mecarbil w leczeniu niewydolności serca u wybranych grup pacjentów
JP2024509797A (ja) 2021-03-10 2024-03-05 アムジェン インコーポレイテッド オメカムチブメカルビルの合成
WO2023205291A2 (en) 2022-04-21 2023-10-26 The Board Of Regents Of The University Of Oklahoma Targeting myocardial tissue for delivery of therapeutic and imaging agents
WO2024081611A1 (en) 2022-10-11 2024-04-18 Cytokinetics, Incorporated Methods for treating heart failure by administering cardiac sarcomere activators
US11986474B1 (en) 2023-06-27 2024-05-21 Cytokinetics, Incorporated Methods for treating heart failure by administering cardiac sarcomere activators

Also Published As

Publication number Publication date
WO2022103966A9 (en) 2022-08-18
HRP20251568T1 (hr) 2026-03-13
CL2023001351A1 (es) 2023-10-20
WO2022103966A1 (en) 2022-05-19
TW202233189A (zh) 2022-09-01
JP2024500616A (ja) 2024-01-10
PT4243825T (pt) 2026-01-30
CA3200673A1 (en) 2022-05-19
IL302850A (en) 2023-07-01
RS67558B1 (sr) 2026-01-30
FI4243825T3 (fi) 2025-12-15
US12194039B2 (en) 2025-01-14
SMT202600073T1 (it) 2026-03-09
LT4243825T (lt) 2026-01-12
AU2021380754A1 (en) 2023-06-22
KR20230107282A (ko) 2023-07-14
AU2021380754A9 (en) 2024-10-24
EP4243825B1 (en) 2025-11-12
CL2024000466A1 (es) 2024-08-30
US20250205228A1 (en) 2025-06-26
US20220184068A1 (en) 2022-06-16
EP4243825A1 (en) 2023-09-20
DK4243825T3 (da) 2025-12-01
MX2023005455A (es) 2023-07-27
EP4706638A2 (en) 2026-03-11
SI4243825T1 (sl) 2026-01-30

Similar Documents

Publication Publication Date Title
LT4243825T (lt) Omekamtivo mekarbilis, skirtas širdies nepakankamumo gydymui pasirinktose pacientų grupėse
IL308698A (en) Tissue treatment system
GB201907283D0 (en) Use of cannabidiol in the treatment of epileptic spams
IL257229A (en) A blood-conducting device for tissue treatment
SG11202108488SA (en) Istaroxime-containing intravenous formulation for the treatment of acute heart failure (ahf)
CA235353S (en) Medical treatment apparatus
CA211022S (en) Medical dressing
GB2602640B (en) Patient treatment facility
IL325238A (en) Semaglutide in medical treatment
GB202011522D0 (en) Neuromodulation for the treatment of circulatory system diseases
IL288678A (en) Treatment of heart failure in human subjects
IL293115B1 (en) Salts and polymorphs of cethromycin for the treatment of disease Salts and polymorphs of cethromycin
EP4470546A3 (en) Regulatory macrophages for treating angiopathies
ES3058993T3 (en) Rxfp1 modulators for the treatment of heart failure
SG11202008536QA (en) Compounds for treatment of cardiac arrhythmias and heart failure
GB202011421D0 (en) Medical gas treatment
EA201890019A1 (ru) Способ профилактики недостаточности трансплантата у реципиента
PL4065134T3 (pl) Doustne podawanie bursztynianu żelaza do stosowania w leczeniu niedoboru żelaza u pacjentów z niewydolnością serca
GB202018725D0 (en) Methods of selecting patients for treatment with combination therapy
CA3294833A1 (en) Semaglutide in medical therapy
GB202203133D0 (en) Patient treatment strategy
GB202102530D0 (en) Method of selecting patients for treatment with combination therapy
WO2014143763A3 (en) Angiogenic compositions for wounds, articular joints and graft materials
GB202217810D0 (en) Medical use
GB202216910D0 (en) Medical use